CAJ | 학술논문

目的：探讨体部立体定向放射治疗（ SBRT）早期非小细胞肺癌患者的临床疗效及不良反应。方法52例经病理组织学和（或）细胞学检查证实的早期NSCLC初治患者入组。 SBRT方式：剂量为4．5～6 Gy/次，每天1次，每周5次，共8～12次，总剂量DT48～56 Gy，以50％～70％等剂量线作为处方剂量线包括90％PTV。结果所有患者均完成治疗，随访率100％，治疗3～6个月后，肿瘤完全缓解率80．8％，部分缓解率17．3％，总有效率98．1％。1、2、3年疾病局部控制率分别为100．0％、96．1％、94．2％。1、2、3年总生存率分别为96．0％、92．3％、82．7％。Ⅱ级放射性肺炎发生率为9．6％，无Ⅱ级以上放射性肺炎发生。结论采取SBRT治疗早期NSCLC的1、2、3年肿瘤局部控制率、疾病相关生存率较高，不良反应较少，值得进一步研究推广。
목적：탐토체부입체정향방사치료（ SBRT）조기비소세포폐암환자적림상료효급불량반응。방법52례경병리조직학화（혹）세포학검사증실적조기NSCLC초치환자입조。 SBRT방식：제량위4．5～6 Gy/차，매천1차，매주5차，공8～12차，총제량DT48～56 Gy，이50％～70％등제량선작위처방제량선포괄90％PTV。결과소유환자균완성치료，수방솔100％，치료3～6개월후，종류완전완해솔80．8％，부분완해솔17．3％，총유효솔98．1％。1、2、3년질병국부공제솔분별위100．0％、96．1％、94．2％。1、2、3년총생존솔분별위96．0％、92．3％、82．7％。Ⅱ급방사성폐염발생솔위9．6％，무Ⅱ급이상방사성폐염발생。결론채취SBRT치료조기NSCLC적1、2、3년종류국부공제솔、질병상관생존솔교고，불량반응교소，치득진일보연구추엄。
Objective To observe the side effects and toxicities of hypofractionated stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer.Methods 52 cases of early stage non-small cell lung cancer patients were treated by SBRT.The 50%-70%dosage curves were selected in the treatment ,2the fractionated doses were 4.5~6 Gy a day,five times a week,totally 8~12 fractions,2the total doses were 48~56 Gy.Results All the patients received the whole treatment , The follow-up rate was 100%.Three to six months after treatment ,2the overall response rate was 98.1%,withCR80.8%,and PR 17.3%.The 1-,2-,and 3-year loal control rates were 100.0%,96.1%,94.2%.The 1-,2-,and 3-year overall survival rates were 96.0%,92.3%,82.7%.The rate of grade 2 radiation pneumonitis was 9.6%and there was no higher grade of radiation pneu-monitis .Conclusion SBRT for early stage non-small cell lung cancer has high 1-,2-,and 3-year tumor control rate ,high surviv-ial rate and less toxicities .It is worth of further study .